Thursday, December 30, 2010

Exercise/Pulmonary Rehab and COPD

Exercise/Pulmonary Rehab and the COPD patient


Patients with chronic obstructive pulmonary disease often report dyspnea (shortness of breath) on exertion and therefore over time tend to decrease their overall activity. Over time this limitation in activity causes an individual to get short of breath with less activity resulting in an individual becoming less active.

Activity is an important component of one’s everyday life; otherwise individuals will have more symptoms with less and less activity. However starting an exercise program is difficult, especially if one is short of breath with minimal activity as many individuals with chronic obstructive pulmonary disease are. Therefore, many individuals limit their activity because any sort of exertion or activity that increases shortness of breath makes them decrease their activity.

Many individuals with COPD are concerned about starting an exercise program and would benefit greatly from guidance from healthcare professionals. If an individual with COPD is apprehensive about exercise or has extremely limited exercise tolerance, they would benefit greatly from a referral to pulmonary rehabilitation.


see more exercise / COPD info at the lung health professional org

Sunday, December 26, 2010

portable lung machine / like the home dialysis machine by Baxter

portable aid machine / like the home dialysis machine by Baxter ?





Just found out today that a friend now has his own dialysis machine at
home, it seems the cost and designs have advanced in the last few years.

How, if this idea can be used for people with emphysema /copd ?
there is a large definite market out there for people suffering from COPD.
The market potential is probably greater than dialysis, I would guesstimate in the millions of potential customers.

Is a home lung machine next ?

A lung machine would concentrate the oxygen and remove the CO2,

about the home dialysis...
HomeChoice PRO™ Baxter Healthcare Corporation SPONSOR
http://www.baxter.com

Purpose: CCPD/APD
Size: 7h x 19.5w x 15.7d inches and 26.8 lbs.
Benefits: Automated dialysis overnight, easy to use, and accurate recording
Special Features: Transfer therapy data from home to dialysis center and vice versa.

Anti-Smoking Campaign: Tar

Anti-Smoking Campaign: Tar




Anti-Smoking Campaign: Tar

Gas Exchange

Gas Exchange within the lung

Gas exchange within your lungs

Short video on how Gas exchanges within your lungs

Respiratory System, Breathing, Lungs

Respiratory System, Breathing, Lungs



Oxygen transport within your body

Oxygen transport within your body


picture of damaged alveoli

picture of damaged alveoli

Friday, December 24, 2010

Photo of a ALung / HemoLung

Pete DeComo, chief executive officer, and Nick Kuhn, chief operating officer of ALung, show off their HemoLung respiratory-assist device that works as an artificial lung for medical patients.


see more info at
http://www.post-gazette.com/pg/10005/1025746-114.stm?cmpid=news.xml#ixzz195CbJVwV

Slide show on the Hemolung br DR Tushar M Chokshi



artificial lung,copd,DR Tushar M Chokshi,hemolung

Pulmonary Reviews is a monthly news magazine

About Pulmonary Reviews

Pulmonary Reviews is a monthly news magazine for physicians who specialize in pulmonary and/or critical care medicine. It provides physicians with information on disorders that affect the lungs and respiratory tract.

Articles cover such topics as asthma, ARDS, pneumonia, influenza, sepsis, emphysema, chronic bronchitis, sleep apnea, AIDS, and pulmonary embolic disease.

Reports on clinical research findings being presented at major American and international medical conferences (including the annual meetings of the American Thoracic Society, the American College of Chest Physicians, the American College of Allergy, Asthma, and Immunology, the Society of Critical Care Medicine, and the European Respiratory Society) as well as incisive reports on significant findings presented in the peer review literature are included in each issue.

Also included are a variety of departmental features, including News Roundup, Clinical Trial Update, New Products, and Literature Monitor.


see the website for Pulmonary Reviews

How about a partial fix/solution for severe COPD / emphysema

 
How about a partial fix/solution for severe COPD / emphysema....?
 
 
 
 
 
 
 


The problem is really 2 parts, O2 input is hindered and carbon dioxide output is limited. Oxygen therapy is a partial solution for the input side of this equation/problem. Has there been any research / thoughts on the 2nd part removing carbon dioxide?





Advanced lung disease is characterised by an inability to remove carbon dioxide from the blood and reduced oxygen uptake efficiency. A shortage of donors can mean long delays and high mortality rates for those awaiting a transplant. The only technology available to aid sufferers during this time is an external lung type of machine.

 

Tuesday, December 21, 2010

what is the National Lung Health Education Program ?

what is the National Lung Health Education Program ?


Who We Are —

The National Lung Health Education Program (NLHEP), was initiated in 1996 as a new healthcare initiative designed to increase awareness of Chronic Obstructive Pulmonary Disease (COPD) among the public and health care professionals and to encourage the use of simple spirometry to make an early diagnosis and monitor ongoing treatment.

The NLHEP initiative is directed to primary care physicians, other healthcare clinicians, government officials, policy makers, health care agencies and especially to patients. Many societies, including governmental agencies support NLHEP, and financial support for our organization comes from a wide range of sources, including unrestricted grants from other non-profit organizations, patient advocacy groups, private donors, along with unrestricted grants from the pharmaceutical and medical support industries.


click to see the offical website National Lung Health Education Program

Saturday, December 18, 2010

UK Lung organization in the UK

1 in 7 people in the UK have some sort of lung problem.
see the UK national website at http://www.lunguk.org/



http://lunguk.org/

Flu problems brewing in the UK

Dr Laurence Buckman, chairman of the British Medical Association's GP committee, has written to the Government urging it to step up its publicity campaign telling people at risk that the vaccine is safe and effective.
He said: 'Family doctors are already seeing high rates of influenza and they have been telling us that they are also seeing a lower uptake than usual for seasonal flu immunisation. 'Myths persist about the safety of the vaccine, especially after swine flu. 'The vaccine has been thoroughly tested and we strongly urge patients to make an appointment with their GP and get vaccinated.

'It is only the beginning of winter so we could see many more cases of flu for the next few months - the BMA strongly urges at-risk groups to get immunised, flu can be extremely serious.'
Overall, 17 people, including four pregnant women, with confirmed swine flu have received specialist intensive care treatment - known as extra corporeal membrane oxygenation (ECMO) - so far this flu season.  ECMO is a life support system for the most severe cases and uses an artificial lung to oxygenate the blood outside the body.
During the pandemic, pregnant women who caught swine flu were found to be more at risk of breathing problems than women who were not pregnant.  Louise Silverton, Deputy General Secretary of the Royal College of Midwives, added: 'Pregnant women should not panic, but we do advise them to have the vaccine and practise good hand hygiene to prevent the spread of germs.

see more info at....
UK GPs warn major flu crisis brewing

Read more: http://www.dailymail.co.uk/health/article-1339564/Pregnant-women-urged-flu-jab-GPs-warn-major-flu-crisis-brewing.html#ixzz18R60f6Mu

Friday, December 17, 2010

Lung Oxygen Measurement / artifical lung

Oxygen MeasurementMeasure Trace & Percent Oxygen Contact Alpha Omega Instrumentswww.aoi-corp.com
An artificial lung for humans and other mammals inserted within the body or placed externally. The artificial lung comprises an electrically actuated three-way valve, a casing containing parallel loops of oxygenator tubes for oxygenation of blood by an atmosphere of circulating air, and an air circulation driving fan powered by an energizing system. As a safety factor in the event of leakage in the casing, a check valve is inserted in an effluent blood duct from the casing to the aerated effluent blood. Two artificial lungs can be utilized internally as left and right lungs.

 
 
 
 
Artificial lung device  United States Patent 6723132
 
 
 
 

Thursday, December 16, 2010

ECMO used for infants



ECMO stands for Extra Corporeal Membrane Oxygenation. ECMO is used in infants who are extremely ill due to breathing or heart problems. The ECMO machine circulates blood through an artificial lung back into the bloodstream. This provides adequate oxygen to the baby while allowing time for the lungs and heart to "rest" or heal.

see source at...
http://www.edward.org/body.cfm?xyzpdqabc=0&id=223&action=detail&AEArticleID=19844&AEProductID=Adam2004_1&AEProjectTypeIDURL=APT_2

Wednesday, December 15, 2010

Lung implant is a breath of fresh air

Lung implant is a breath of fresh air December 2010







Artificial lung technology could reduce the death rate for patients awaiting a lung transplant, say US scientists.

Advanced lung disease is characterised by an inability to remove carbon dioxide from the blood and reduced oxygen uptake efficiency. A shortage of donors can mean long delays and high mortality rates for those awaiting a transplant. The only technology available to aid sufferers during this time is based in intensive care units, hindering quality of life.

Now, Joseph Vacanti and coworkers at Massachusetts General Hospital, Boston, have developed a device that achieves the CO2/O2 gas exchange that, when implanted in the body, could allow patients more freedom when awaiting a transplant. Their design is a microfluidic branched vascular network through which blood flows, separated from a gas-filled chamber by a silicone membrane less than 10um thick. The network is formed by casting polydimethylsiloxane, a biocompatible polymer, on a micro machined mould.

A device that achieves carbon dioxide/oxygen gas exchange could allow patients more freedom when awaiting a lung transplant

A major challenge faced by Vacanti's team was achieving a blood pressure within the device's channels similar to that in veins and arteries. They applied computational fluid dynamics to optimise the vascular network's structure to avoid clotting induced by excessive blood pressure. 'Fulfilment of these design criteria necessitated creating channels that had variable depth throughout the network and also had precise curvature,' says Vacanti's coworker, David Hoganson.

Vacanti's device could be scaled up for implantation. According to Hoganson, an implant-sized device could be fabricated by 'stacking the functional layers of the device to achieve the necessary surface area for gas exchange'.

Jaisree Moorthy, who specialises in using microfluidics in tissue engineering at the University of Pennsylvania, says that Vacanti's device provides a very elegant solution. Compared to existing devices, Moorthy comments that it 'is more efficient due to a thinner membrane, and mimics the biological CO2/O2 transfer rate'.

In the future, Vacanti hopes to develop the device further to incorporate engineered lung tissue.

Link to journal articleLung assist device technology with physiologic blood flow developed on a tissue engineered scaffold platform

David M. Hoganson, Howard I. Pryor II, Erik K. Bassett, Ira D. Spool and Joseph P. Vacanti, Lab Chip, 2011

DOI: 10.1039/c0lc00158a


Now, Joseph Vacanti and coworkers at Massachusetts General Hospital, Boston, have developed a device that achieves the CO2/O2 gas exchange that, when implanted in the body, could allow patients more freedom when awaiting a transplant.


ChemScience Volume 2010 12 lung implant breath fresh air click to see source

see more info on this lung implant method procedure

Tuesday, December 14, 2010

MORE COPD PATIENTS COULD BENEFIT FROM OXYGEN THERAPY

MORE COPD PATIENTS COULD BENEFIT FROM OXYGEN THERAPY

The website 6-minutes, a daily newsletter for Australian doctors, reports on a study that finds many patients ineligible for supplemental oxygen under current criteria could still benefit from oxygen therapy. They conclude that a single daytime measurement of oxygen in the blood may not be the best method of determining who could benefit from oxygen therapy. Researchers find a large number of people are okay during the day, but have oxygen saturations below 90 percent at night. For more information, see:

More COPD patients could benefit from oxygen

Many COPD patients with borderline hypoxaemia would benefit from long term oxygen therapy but are currently excluded due to misleading one-off measurements of oxygenation, Victorian researchers say.

A study of 35 COPD patients with moderate hypoxaemia on resting showed that 24-hour oximetry was able to identify a large subgroup of patients who had clinically significant hypoxaemia throughout the day and especially at night.

The use of ambulatory oximetry showed that 54% of patients spent more than 30% of the monitoring period with oxygen saturation below 90%, “suggesting a significant degree of hypoxaemia that is often missed by point measurement of PaO2,” say the researchers from Barwon Health in the Internal Medicine Journal (online 1 December) .

“We believe this group may include patients with the potential to benefit from this therapy [despite] being ineligible for prescription of long term oxygen therapy according to current criteria,” they write.

The study authors say long term oxygen therapy is known to improve survival, pulmonary dynamics and exercise capacity in patients with severe hypoxaemia, but currently eligibility for oxygen therapy is decided by point measurement of PaO2.

The study also showed that BMI was correlated with daytime hypoxaemia, whereas age and PaO2 were the only significant predictors of nocturnal hypoxaemia.

“Our findings suggest that a single daytime measurement of resting PaO2 may not be the optimal method for determining which patients will benefit from this approach to nocturnal oxygen prescription,” they say.

By Michael Woodhead

New lung disease network to benefit patients and boost UK economy

New lung disease network to benefit patients and boost UK economy



Scientists and clinicians in Nottingham are to work more closely with industry to develop new ways of diagnosing and treating lung disease.

Nottingham has been chosen as one of just nine centres across the UK to host a Government-spearheaded ‘Therapeutic Capability Cluster’, which aims to forge closer links between academia, the NHS and the life sciences industry to speed up the process of getting new drugs from lab bench to bedside.

The new cluster will draw on the world-leading research expertise of scientists at The University of Nottingham and clinical excellence of Nottingham University Hospitals NHS Trust to help pharmaceutical companies develop clinical trials for potential new treatments for a range of respiratory diseases.


see more at...
http://www.nottingham.ac.uk/news/pressreleases/2010/december/lungdiseasenetwork.aspx

Wednesday, December 8, 2010

U.S. servicemember survive having a lung removed downrange

Doctors say Griego — of Apache Troop, 1st Squadron, 75th Cavalry Regiment, 101st Airborne Division — is also the first U.S. servicemember in the Iraq and Afghanistan wars to survive having a lung removed downrange.

His journey back started with the brave actions of his fellow soldiers. Griego and his unit were securing a road in southern Afghanistan on Oct. 19 when Taliban fighters opened fire from a nearby building. Griego was shot in the chest, and blood spewed from a bullet wound under his right ribs. Sgt. Matt Casting and Sgt. Mark Reed stanched it, keeping Griego from hemorrhaging, the most common cause of combat death.

Then, amid the heated firefight, the unit’s medic, Spc. Allan Hughes, ran 650 meters to reach Griego, who was laboring to breathe because air was building in his lung cavity, putting pressure on his lungs to the point of near collapse. Hughes thrust a thick, long needle into Griego’s chest, relieving the pressure and saving his life yet again.

Advertisement
Minutes later, Griego was evacuated to the Role 3 hospital in Kandahar. There doctors discovered a tiny wound near the left side of Griego’s neck. This told them that the bullet had torn through his chest cavity, likely injuring both lungs, said U.S. Navy Dr. (Cmdr.) Eric Elster, director of surgical services at the hospital.

They wheeled Griego into the operating room. Elster and a team of surgeons searched for the severed vessels that poured blood into Griego’s lungs. They stapled off the top of Griego’s left lung, stemming the bleeding there.

But his right lung was full of holes. Despite their best efforts to stop all the leaks, the doctors could not control the bleeding, Elster said. So the surgeons clamped off the blood flow to the right lung, ensuring that it would have to be removed later.

A CT scan showed the bullet’s path through Griego’s chest. It had punctured his right chest near his back and then ricocheted off his spine — somehow not injuring it — and out the top of his left neck.

“He did have injuries to both his lungs,” Elster said. “But this was kind of a lucky shot, in that he did not have any other injuries to his spinal cord or esophagus that would have magnified it.”

The next morning surgeons removed Griego’s right lung, a procedure rarely attempted downrange. They also called Landstuhl Regional Medical Center’s Lung Rescue Team, which flies to combat zones and retrieves servicemembers with serious lung injuries.

The lung team landed in Kandahar that afternoon and tried several different ventilators on Griego, attempting to force air into his remaining lung to make him stable for flight. But all the ventilators failed, and Dr. (Lt. Col.) Sandra Wanek, who led the combat evacuation mission, chose to use a portable heart-lung machine that performs a therapy called extracorporeal membrane oxygenation, or ECMO.

The device, about the size of a suitcase, forces the blood through an artificial membrane that lets in oxygen while taking out carbon dioxide — mimicking the trade-off that naturally takes place in the lungs. The machine worked even better than Wanek expected, and by the time the team landed at Landstuhl several hours later on Oct. 20, Griego’s condition had started to improve.

He was then flown to the university hospital in Regensburg, Germany, where doctors have particular expertise with the portable ECMO machine. Doctors there had also trained Wanek and her team how to use the device in July.

Developed in the 1980s as a way to save the lives of premature infants with underdeveloped lungs, ECMO was never formally approved as a therapy in the United States because the machine was used only as a last-ditch, life-prolonging measure. Recently, however, ECMO machines have been used to treat patients with lung failure, including H1N1 influenza patients, with better prognoses.

Maquet, the company that developed the portable ECMO machine, is trying to get it approved for broader use in the U.S., particularly with patients suffering lung or heart failure who need to be transported.

A ruling by the U.S. Food and Drug Administration is expected sometime next year, but Wanek said she knows what would have happened to Griego had he received same gunshot wound stateside.

“This happens to you in Los Angeles,” she said, “ and the mortality rate is about 70 percent.”

A ventilator, Wanek explained, pushes air into the lungs, but that process can further injure, or even kill, patients whose lungs are damaged and weak.

The ECMO machine bypasses the lungs entirely. At the Regensburg hospital, Griego was kept sedated as the machine controlled the oxygen and carbon dioxide in his bloodstream. His remaining lung was left to heal.

There, Peter Griego read to his son from several hunting magazines, telling him about the latest rifles and archery bows — unsure whether they would again go hunting for deer and elk in mountains a few hours from their home in Mesa, Ariz. A weak squeeze of the hand was the only indication that his son could hear him. But Griego’s remaining lung slowly recovered, and doctors started forcing it to take “baby breaths,” Wanek said.

“As the lung was doing better,” she said, “we were able to let the lung do a little more, and the machine do a little less.”

After more than two weeks at the Regensburg hospital, Griego was taken off the ECMO machine. He returned to Landstuhl, where his tracheotomy tube was also removed, allowing him to talk in whispers when his father held two fingers over his open windpipe.

In Landstuhl’s intensive care unit, Griego sat up for the first time Nov. 8. His 17-year-old brother, Peter Jr., placed headphones on his ears, letting him listen to a favorite ’90s hip-hop group, Atmosphere. Griego’s lips mouthed the words of the songs, and Griego squeezed his younger brother’s hand when he wanted the tune changed.

Wanek said she expected Griego to make a full recovery, “in that he will go home and live a normal life. He just needs to get used to having a lot less lung.”

Griego was eventually flown to Brooke Army Medical Center in San Antonio, where he began physical therapy. He regained the ability to speak on his own last week, and this week he will join his family at the Fisher House to eat turkey and celebrate Thanksgiving.

“It’s my favorite holiday because all of my family is there,” he said. “This time it’s going to be my immediate family and the wounded soldiers and their families. But I definitely think this Thanksgiving will mean the most to me.”

Afterward, his recovery will continue. His legs are weak, but he has started to walk with the help of a family member or a walker.

“I still get winded just sitting up. I yawn like a baby, and when I need to take a deep breath I can tell that it’s not all there,” he said of his missing lung.

None of the doctors have been able to tell Griego precisely what physical limitations he can expect, beyond acknowledging that he will likely not run a marathon anytime soon.

“I think everybody is still amazed that I made it,” he said. “And they are just as curious as me.”

The only family member still unaware of Griego’s injuries and miraculous recovery is his 4-year-old daughter, Rylie.

“I haven’t called her because I’m not sure what I want to tell her,” he said. “But her mother told me she says a prayer for her daddy and his Army buddies every night.”

robbinss@estripes.osd.mil
see more at
http://www.stripes.com/family-thankful-for-medical-innovation-and-for-a-soldier-s-survival-1.126242?localLinksEnabled=false

Monday, December 6, 2010

iLA Membrane Ventilator is the first artificial lung ....

iLA Membrane Ventilator

Hohlfasermembran
A special hollow-fiber membrane assumes the function of pulmonary alveoli.

PaCO2_pH
Effective and reliable: the iLA Membrane Ventilator® (Source: Novalung Support Registry 2008)

The iLA Membrane Ventilator® is the first artificial lung that breathes for the patient outside the body. It removes carbon dioxide outside of the lung, and is perfused by the heart like a natural organ. This relieves the patient’s lung by providing gas exchange support and reducing the workload for the breathing pump. The lung is given “Time to Heal“®.
The iLA Membrane Ventilator® is sometimes referred to in scientific articles as “pecla“ (pumpless extracorporeal lung assist) or ”AVCO2R“ (arterio-venous CO2 removal).

iLA Membranventilator Gas exchange via artificial alveoles

A hollow-fiber membrane is responsible for gas exchange in the artificial lung, which measures only 14 by 14 cm, supporting or even replacing mechanical ventilation. The iLA Membrane Ventilator® is connected to the patient via two NovaPort® femoral cannulas in an arterio-venous circuit. The absence of a mechanical blood pump reduces the risk of inflammatory reactions.

How it works: effective and reliable

The iLA Membrane Ventilator® incorporates a heparin-coated hollow-fiber diffusion membrane and removes carbon dioxide effectively and reliably in a very short period of time to achieve the desired target, using low blood flows of approx. 1 L/min. This extrapulmonary ventilation can be controlled via the sweep gas flow. In cases of respiratory acidosis the pH is generally returned to normal physiological levels within a few hours. This can help protect the kidney and other organs and prevent multi-organ failure.

Easy to use and easy to care for

Positioning therapy and initial mobilization are possible with the iLA Membrane Ventilator thanks to the 360° rotating curve connectors. It is also been used for both inter-hospital and intra-hospital transport. The iLA Membrane Ventilator® was developed for temporary use in intensive-care patients and is approved in Europe for up to 29 days.








click to see more info on this artifical lung by Novalung


Saturday, December 4, 2010

Persistence of tungsten oxide particle/fiber mixtures in artificial human lung fluids

Persistence of tungsten oxide particle/fiber mixtures in artificial human lung fluids

During the manufacture of tungsten metal for non-sag wire, tungsten oxide powders are produced as intermediates and can be in the form of tungsten trioxide (WO3) or tungsten blue oxides (TBOs). TBOs contain fiber-shaped tungsten sub-oxide particles of respirable or thoracic size.

The aim of this research was to investigate whether fiber-containing TBOs had prolonged biodurability in artificial lung fluids compared to tungsten metal or WO3 and therefore potentially could pose a greater inhalation hazard.

Methods: Dissolution of tungsten metal, WO3, one fiber-free TBO (WO2.98), and three fiber-containing TBO (WO2.81, WO2.66, and WO2.51) powders were measured for the materials as-received, dispersed, and mixed with metallic cobalt. Solubility was evaluated using artificial airway epithelial lining fluid (SUF) and macrophage phagolysosomal simulant fluid (PSF).

see  more at
http://7thspace.com/headlines/365713/persistence_of_tungsten_oxide_particlefiber_mixtures_in_artificial_human_lung_fluids.html